SCHEMBL10055064

SCHEMBL10055064

Cc1ccc(NCc2ccc(CNc3ccccc3)c3ccccc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.61
MAPT P10636 6/20 0.59
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
MAOB P27338 2/20 0.54
MAOA P21397 1/20 0.54
HPGD P15428 2/20 0.50
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 2/20 0.49
ALOX15 P16050 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
USP2 O75604 1/20 0.49
TP53 P04637 1/20 0.49
ALOX12 P18054 1/20 0.49
CCNE1 P24864 2/20 0.48
CDK2 P24941 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10055005 0.88 MAPT (0.57) HTTMAPTKMT2AMEN1MAOB
SCHEMBL11510867 0.77 MAPT (0.68) HTTMAPTKMT2AMEN1MAOB
N-Benzyl-4-Methylaniline SCHEMBL171785 0.76 HTT (1.00) HTTMAPTKMT2AMEN1HPGD
SCHEMBL1624682 0.76 HTT (0.84) HTTMAPTKMT2AMEN1HPGD
SCHEMBL11530504 0.76 MAPT (0.81) HTTMAPTKMT2AMEN1HPGD
SCHEMBL13119267 0.75 HRH3 (0.59) HTTMAPTKMT2AMEN1ALDH1A1
N-Benzyl-4-Methylaniline SCHEMBL9771340 0.75 HTT (0.96) HTTMAPTKMT2AMEN1HPGD
N-Benzyl-4-Methylaniline SCHEMBL28183543 0.75 HTT (0.96) HTTMAPTKMT2AMEN1HPGD
SCHEMBL30301294 0.74 MAPT (1.00) HTTMAPTKMT2AMEN1MAOB
SCHEMBL28870076 0.74 MAPT (0.70) HTTMAPTKMT2AMEN1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160002174-A1 CXCR4 Antagonists for the Treatment of Medical Disorders EMORY UNIVERSITY 2016-01-07 US disclosed
US-20160002174-A1 CXCR4 Antagonists for the Treatment of Medical Disorders EMORY UNIVERSITY 2016-01-07 US disclosed
US-20140039187-A1 CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS EMORY UNIVERSITY 2014-02-06 US disclosed
US-20140039187-A1 CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS EMORY UNIVERSITY 2014-02-06 US disclosed
US-8114884-B2 CXCR4 antagonists for the treatment of medical disorders EMORY UNIVERSITY (US) 2012-02-14 US disclosed
US-8114884-B2 CXCR4 antagonists for the treatment of medical disorders EMORY UNIVERSITY (US) 2012-02-14 US disclosed
US-20070054930-A1 CXCR4 antagonists for the treatment of medical disorders EMORY UNIVERSITY 2007-03-08 US disclosed
US-20070054930-A1 CXCR4 antagonists for the treatment of medical disorders EMORY UNIVERSITY 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054930-A1 CXCR4 antagonists for the treatment of medical disorders CXCR4, CXCL12, CXCR1 HTT 3705/4885MAPT 4435/4885KMT2A 3853/4885
US-20160002174-A1 CXCR4 Antagonists for the Treatment of Medical Disorders CXCR4, CXCL12, CXCR1 HTT 3705/4885MAPT 4435/4885KMT2A 3853/4885
US-20140039187-A1 CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS CXCR4, CXCL12, CXCR1 HTT 3705/4885MAPT 4435/4885KMT2A 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.